ELTX News

Elicio Therapeutics, a Phase 1/2 biotech developing novel immunotherapies for cancer, withdrew its plans for an initial public offering on Tuesday. It had filed in June 2021, setting terms the following July to raise $40 million by offering 3.1 million shares at a price range of $12 to $14. Elicio's lead candidate, ELI-002, is being developed to treat cancers driven by...read more

Updated Monday, 7/19. The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 19 IPOs slated to raise $5.2 billion. The largest deal of the week, specialty insurance brokerage Ryan Specialty Group (RYAN) plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard...read more

Elicio Therapeutics, a Phase 1/2 biotech developing novel immunotherapies for cancer, announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $40 million by offering 3.1 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Elicio Therapeutics would command a fully diluted market value of $201 million. Elicio's...read more

Elicio Therapeutics, a Phase 1/2 biotech developing novel immunotherapies for cancer, filed on Monday with the SEC to raise up to $10 million. Elicio's lead candidate, ELI-002, is being developed to treat cancers driven by KRAS, a mutation found in approximately 25% of tumors. The company is conducting a Phase 1/2 trial of ELI-002 and anticipates initial safety,...read more